Spring L et al. -pCR after neoadjuvant therapy has been shown to be a surrogate marker for DFS and OS, but the association between pCR and survival outcomes in young women with breast cancer has not been established. Based on the current study, pCR after neoadjuvant chemotherapy was shown to be associated with improved DFS and OS.

Methods

• Women ≤ 40 years of age at the time of diagnosis who received neoadjuvant chemotherapy for stage II–III invasive breast cancer were enrolled.

Results

• Of 170 women, 53 achieved a pCR.
• The 5-year DFS for patients with and without pCR was 91% versus 60%, respectively.
• The OS was 95% versus 75%, respectively.